Department of Ophthalmology and the Department of Radiotherapy and Radiobiology, Medical University of Vienna 1090 Vienna AustriaRekrutierend» Google-Maps Ansprechpartner: Martin Zehetmayer, MD Phone: +431 40400 Phone (ext.): 7941 E-Mail: martin.zehetmayer@meduniwien.ac.at» Ansprechpartner anzeigen
The purpose of this study is to assess the safety and efficacy of hypofractionated
stereotactic LINAC radiotherapy with 10 fractions at 6 Gy per fraction at the 80% isodose for
the planning target volume (PTV) in patients with uveal melanoma. Patients will be
followed-up for 10 years after radiotherapy regarding local tumor control, visual acuity,
secondary complications and survival.
- The initial height of the melanoma is 7 mm or higher.
- Juxtapapillary and/or juxtamacular melanomas with a height of 3 mm or higher and if
the central tumor distance to the optic disc and/or the macula is 3 mm or less.
- If other forms of conservative treatment of the melanoma are not possible.
Exclusion Criteria:
- Prior/Concomitant Treatment.
- Extrascleral tumor extension is present.
- If the presence of neovascular glaucoma is detected before treatment.
- If metastasis is detected at baseline.
- Previous participation in any study of investigational drugs within 3 month preceding
day 0.
- Pregnant women are not allowed to participate in the study.
Hypofractionated linear accelerator radiotherapy: 10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!
